GenSight Biologics Completes €2.9 Million Fundraising

GenSight Biologics, a biopharma company focused on gene therapies for retinal and central nervous system disorders, announced the completion of a €2.9 million fundraising. Subscribed by shareholders Heights Capital, Invus, and Alumni Capital, this follows previous fundraisings totaling €10.2 million this year. The funds are primarily intended for the development of GS010/LUMEVOQ®, aiming to secure operational continuity into 2026.

CEO Laurence Rodriguez highlighted the compassion use approvals in the US, France, and Israel as key milestones. CFO Jan Eryk Umiastowski emphasized investor confidence as a driver for growth. The shares will be listed on Euronext Paris, while revenues from compassionate access programs are expected to support financial stability.

Despite successful fundraising, GenSight aims to continue sourcing funds to support upcoming trials and operational needs in the next year.